Given the diversified immunomodulatory function of CD38, it remains unclear to what extent the actual efficacies of daratumumab in AML are recapitulated in immunodeficient NSG mice lacking functional B cells, T cells and natural killer cells. This evidence concerns the gene CD38 and acute myeloid leukemia.